Drug Candidate Marketplace
Drug Candidate Marketplace lists the information of drug candidates, therapeutic targets and drug discovery technologies. Visitors can use search functions based on the interests and needs. If you have a drug candidates, therapeutic targets and drug discovery technologies that you are interested in and would like to gain more information, please contact us by clicking the inquiry button. After consenting to the terms of condition and use of our services, the requested information will be provided to you.
|Date||Candidate||Mechanism of action||Indication||Route||Development stage||Note|
|07/05/18||GEM023||Synthetic miniprotein for influenza virus||Infuenza||Preclinical||Computationally designed miniprotein with demonstrated pre and post-exposure efficacy against the disease.
-Neutralizes multiple variants like H1N1 and H5N1 better than today’s standard of care while keeping immunogenicity low enough to allow chronic treatments.
Route : Inhaled
|07/05/18||GEM022||Computational drug design platform for synthetic miniproteins||asthma, flu and neuropathic pain etc.||Discovery||-High-value, high-complexity protein design by computational and high-throughput techniques.
-Mimics proven monoclonal antibodies with safer, more effective biologic alternatives.
-Designed to a specific drug target epitope with sub-nM affinity.
Route : Inhaled, Oral, Topical, IV
|07/05/18||GEM021||Opioid and non-opioid analgesics with respiratory stimulant||Pain||Oral||Preclinical （close to IND）||-Combination of generic opioid/non-opioid analgesics with a generic respiratory stimulant using a regulatory approach known as the 505(b)2 submission.
-First drug introduction therapeutically equivalent to Vicodin® that prevents overdose death, deters abuse and prevents addiction.
-Low cost of goods.
|06/04/18||GEM020||3rd generation immunotherapy targeting little gastrin||Gastro-intestinal cancer （Pancreatic）||SC||Preclinical||-Applied 3rd generation immunotherapy technology to little gastrin.
-In-vivo POC has been validated in non-human primates.
|06/04/18||GEM019||3rd generation immunotherapy targeting HER2||HER2 overexpressing cancer （Breast）||SC||Preclinical||-Applied 3rd generation immunotherapy technology to HER2.
-Superior efficacy to trastuzumab and pertuzumab.
-In-vivo PoC has been validated in non-human primates.
|06/04/18||GEM018||3rd generation immunotherapy technology||Cancer||SC||Discovery||-Unique technology that triggers B and T cells simultaneously while activating all possible natural tumor killing mechanisms available to the immune-system.
-Tumor-directed specific activation reduces side effects to the minimum.
-Applicable on a target basis.
|05/31/18||GEM009||BET inhibitor||Cancer, Rheumatoid Arthritis||Oral||Preclinical||More potent activities and lower risk of cardiovascular toxicities than competitors||Contact|
|04/10/18||GEM008||Selective cMET inhibitor||NSCLC and HCC etc.||Oral||Phase 2||Effective on exon 14 skipping xenograft||Contact|
|03/26/18||GEM007||Vaccine||Anthrax||Oral||Discovery~ Preclinical||A cost-effective and safer vaccine that would produce immunity to anthrax with fewer doses||Contact|
|03/26/18||GEM006||Bacterial NADH production inhibitor||Bacterial infection||Discovery~ Preclinical||Inhibits synthesis of NADH in bacteria, but not in humans and expected to be used for treatment of multi-drug resistant pathogens||Contact|